查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1518490

傳染性腸炎治療市場 - 按藥物類型、給藥途徑、藥物類型、配銷通路- 全球預測

Infectious Enteritis Treatment Market - By Drug Type, Route of Administration, Medication Type, Distribution Channel - Global Forecast
出版日期: | 出版商: Global Market Insights Inc. | 英文 170 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於該領域持續的研發工作，2024 年至 2032 年間，全球傳染性腸炎治療市場的複合年成長率將達到 5.5%。腸炎的特徵是通常由感染引起的腸道炎症，對全球健康構成重大挑戰。了解病原體機制、診斷工具和治療方案的進展正在推動創新。研究人員正在探索專門針對引起腸炎的特定病原體而設計的新型抗生素、益生菌和抗病毒藥物。

例如，2021 年 2 月，梅奧診所的研究人員進行了一項最新研究，旨在調查一大群已確診的彎曲桿菌感染患者的盛行率、與 PI-IBS 相關的症狀類型以及危險因子。 「我們的研究結果表明，五分之一的被診斷出患有彎曲桿菌感染的人可能會出現類似於腸躁症的慢性胃腸道症狀，」格羅弗博士解釋。

此外，疫苗開發的進步有望針對輪狀病毒和諾羅病毒等傳染源採取預防措施。腸道感染盛行率的上升及其對公共衛生的影響凸顯了有效治療的迫切性。隨著研究不斷發現新的見解和治療策略，傳染性腸炎治療市場有望擴大，為這些使人衰弱的疾病提供更好的結果和更好的管理。

整體感染性腸炎治療產業規模根據藥物類型、給藥途徑、配銷通路和地區進行分類。

抗寄生蟲藥領域將在2024年至2032年經歷嚴格發展。抗寄生蟲藥物在有效管理這些病症、縮短病程和改善患者預後方面發揮著至關重要的作用。隨著研究的進步和診斷能力的提高，對具有功效、安全性和便利性的創新抗寄生蟲藥物的需求持續成長。這一趨勢強調了開發和提供有效治療方法的重要性，以滿足患有寄生蟲引起的傳染性腸炎的患者不斷變化的需求。

注射劑領域的傳染性腸炎治療市場收入將在2024 年至2032 年實現顯著的複合年成長率。療效。它們對於住院患者或因胃腸道症狀而無法耐受口服藥物的患者特別有價值。由於製劑技術的進步提高了藥物穩定性和生物利用度，傳染性腸炎治療中的注射療法市場正在擴大。這一趨勢反映了醫療保健行業致力於透過針對嚴重胃腸道感染的可用且有效的治療方案來改善患者的治療結果。

歐洲傳染性腸炎治療市場從2024年到2032年將呈現出值得稱讚的複合年成長率。隨著醫療保健提供者優先考慮早期檢測和量身定做的治療干預措施，市場正在擴大。此外，監管支持和研究措施有助於創新療法的開發，滿足該地區多樣化的醫療保健需求。由於腸炎的流行仍然是一個公共衛生問題，整個歐洲對可靠、有效的治療解決方案的需求持續成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 食源性疾病發生率增加
      • 不斷成長的研發活動
      • 提高認知和教育
      • 人口老化加劇
    • 產業陷阱與挑戰
      • 抗生素抗藥性的出現
      • 複雜而嚴格的監管要求
  • 成長潛力分析
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略展望矩陣

第 5 章：市場估計與預測：按藥物類型，2021 - 2032

  • 主要趨勢
  • 抗生素
  • 抗寄生蟲藥
  • 抗痙攣藥
  • 其他藥物種類

第 6 章：市場估計與預測：按管理途徑，2021 年至 2032 年

  • 主要趨勢
  • 口服
  • 可注射

第 7 章：市場估計與預測：按藥物類型，2021 - 2032

  • 主要趨勢
  • 品牌化
  • 泛型

第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 9 章：市場估計與預測：按地區分類，2021 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 10 章：公司簡介

  • Abbott Laboratories
  • Almirall SA
  • AstraZeneca PLC
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche Ltd
  • GSK plc
  • Medimetriks Pharmaceuticals Inc.
  • Merck KGaA
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Ltd.
簡介目錄
Product Code: 9216

Global Infectious Enteritis Treatment Market will witness 5.5% CAGR between 2024 and 2032 due to ongoing research and development efforts in the field. Enteritis, characterized by inflammation of the intestine typically caused by infections, poses significant health challenges globally. Advances in understanding pathogen mechanisms, diagnostic tools, and treatment options are driving innovation. Researchers are exploring novel antibiotics, probiotics, and antiviral agents tailored to combat specific pathogens responsible for enteritis.

For instance, in February 2021, Mayo Clinic researchers conducted a recent study to investigate the prevalence, types of symptoms associated with PI-IBS, and risk factors in a large cohort of patients with confirmed campylobacter infection. "Our findings indicated that 1 in 5 individuals diagnosed with campylobacter infection may develop chronic GI symptoms resembling irritable bowel syndrome," explained Dr. Grover.

Moreover, advancements in vaccine development hold promise for preventive measures against infectious agents like rotavirus and norovirus. The rising prevalence of enteric infections and their impact on public health underscore the urgency for effective treatments. As research continues to uncover new insights and therapeutic strategies, the Infectious Enteritis Treatment Market is poised to expand, offering improved outcomes and better management of these debilitating conditions.

The overall infectious enteritis treatment Industry size is classified based on the drug type, route of administration, distribution channel, and region.

The antiparasitics segment will undergo rigorous development from 2024 to 2032. Enteritis caused by parasites such as Giardia and Cryptosporidium requires targeted treatments to alleviate symptoms and eradicate infections. Antiparasitic drugs play a crucial role in effectively managing these conditions, reducing disease duration, and improving patient outcomes. As research advances and diagnostic capabilities improve, the demand for innovative antiparasitics that offer efficacy, safety, and convenience continues to grow. This trend underscores the importance of developing and delivering effective treatments to meet the evolving needs of patients suffering from infectious enteritis caused by parasitic organisms.

The infectious enteritis treatment market revenue from the injectable segment will register a notable CAGR from 2024 to 2032. Injectable treatments play a pivotal role in managing severe cases of enteritis caused by bacterial or viral infections, providing rapid delivery and efficacy. They are particularly valuable in hospitalized patients or those unable to tolerate oral medications due to gastrointestinal symptoms. The market for injectable therapies in infectious enteritis treatment is expanding due to advancements in formulation technology, which enhance drug stability and bioavailability. This trend reflects the healthcare industry's commitment to improving patient outcomes through accessible and effective treatment options for serious gastrointestinal infections.

Europe infectious enteritis treatment market will showcase a commendable CAGR from 2024 to 2032. European countries are investing in advanced diagnostic tools and effective treatment options to combat enteritis caused by various pathogens. The market is expanding as healthcare providers prioritize early detection and tailored therapeutic interventions. Additionally, regulatory support and research initiatives contribute to the development of innovative treatments, meeting the region's diverse healthcare needs. As the prevalence of enteritis remains a public health concern, the demand for reliable and efficient treatment solutions continues to rise across Europe.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing incidence of foodborne disease
      • 3.2.1.2 Growing R&D activities
      • 3.2.1.3 Increasing awareness and education
      • 3.2.1.4 Growing ageing population
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Emergence of antibiotic resistance
      • 3.2.2.2 Complex and stringent regulatory requirements
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Antibiotics
  • 5.3 Antiparasitics
  • 5.4 Anti-spasmodics
  • 5.5 Other drug types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Oral
  • 6.3 Injectable

Chapter 7 Market Estimates and Forecast, By Medication Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Branded
  • 7.3 Generics

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 Almirall SA
  • 10.3 AstraZeneca PLC
  • 10.4 Bristol-Myers Squibb
  • 10.5 F. Hoffmann-La Roche Ltd
  • 10.6 GSK plc
  • 10.7 Medimetriks Pharmaceuticals Inc.
  • 10.8 Merck KGaA
  • 10.9 Pfizer Inc.
  • 10.10 Teva Pharmaceutical Industries Ltd.
  • 10.11 Zydus Lifesciences Ltd.